115PD - Brain metastases (BM) development after chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter?

Date 14 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Predictive models for chemo- and radiotherapy
Topics Cytotoxic agents
Surgical oncology
Non-small-cell lung cancer
Biological therapy
Radiation oncology
Presenter Lizza Hendriks
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors L. Hendriks1, A. Brouns2, M. Amini3, W. Uyterlinde4, R. Wijsman5, B. Biesma3, J. Stigt6, D. De Ruysscher7, M. Van den Heuvel8, A. Dingemans1
  • 1Pulmonary Diseases, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 2Pulmonary Diseases, Zuyderland Hospital, Heerlen/NL
  • 3Pulmonary Diseases, Jeroen Bosch Hospital, 's-Hertogenbosch/NL
  • 4Thoracic Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam/NL
  • 5Radiation Oncology, Radboud University Medical Centre Nijmegen, Nijmegen/NL
  • 6Pulmonary Diseases, Isala Klinieken, Zwolle/NL
  • 7Radiation Oncology, Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht/NL
  • 8Thoracic Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL



BM occur frequently within 1 year after CRT for stage III NSCLC. It is unknown whether the specific chemotherapy used influences subsequent BM development.


Retrospective multicenter study including all consecutive stage III NSCLC patients (pts) who completed CRT. Primary endpoints: BM development within the 1st year and whether this was the only site of first relapse. Differences between regimens were assessed with a logistic regression model including known BM risk factors (age, gender, histology, T- and N-status) and the specific chemotherapy used (concurrent (cCRT) vs sequential (sCRT), within cCRT: low dose cisplatin monotherapy (LDC) – high dose polychemotherapy; (non-)taxane high dose polychemotherapy – LDC; chemotherapy subgroups of ≥50 pts).


Between January 2006 and June 2014, 838 pts were eligible (737 cCRT, 101 sCRT). 11% developed BM within a year, 5% had BM as only site of first relapse. BM pts were significantly younger (mean age 59 vs 63 years, p 


Approximately 1 out of 10 pts will develop BM within the 1st year after stage III NSCLC diagnosis, but this does not depend on the type of chemotherapy regimen used within a CRT regimen.

Clinical trial identification

not applicable

Legal entity responsible for the study





All authors have declared no conflicts of interest.